US Patent IssuedNew Zealand Pharmaceuticals Ltd is pleased to announce that the U.S. patent 8,420,063,…
Application of N-acetylmannosamineThe application of N-acetylmannosamine to the mammalian cell culture production of…
NZP is certified ISO 14001New Zealand Pharmaceuticals Ltd is proud to announce that is has been audited by TELARC…
|
National Human Genome Research Institute (NHGRI) (Bethesda, MD; www.genome.gov) and New Zealand Pharmaceuticals Ltd (NZP) (Palmerston North, New Zealand; www.nzp.co.nz) have partnered on a drug development project. The goal is to reduce or halt the progression of a rare disorder, Hereditary Inclusion Body Myopathy (HIBM) by treating affected patients with a small molecule therapeutic drug. HIBM primarily affects distal muscle tissue, and due to dramatically decreased muscle strength, most HIBM patients must use a wheelchair by the time they are in their 30s. NZP has licensed NHGRI’s patent portfolio related to treating HIBM and other muscle wasting diseases, as well as kidney diseases related to hyposialylation, with a monosaccharide N-Acetyl-D-mannosamine (ManNAc), also known as DEX-M74. DEX-M74 is one of the first molecules to enter development in the Therapeutics for Rare and Neglected Diseases (TRND) program (http://nctt.nih.gov/trnd) at the National Institutes of Health (NIH). NZP and TRND are currently collaborating to complete needed pre-clinical studies for treating HIBM with DEX-M74 - these studies will be the basis of an investigational new drug application (IND) to be submitted to the Food and Drug Administration (FDA). Once the IND goes into effect, a phase I/II clinical trial is scheduled to begin at the NIH Clinical Center. That study will be led by HIBM expert and NHGRI Clinical Director, Dr. William Gahl, M.D., Ph.D.
NZP produces of a range of bulk pharmaceutical intermediates and pharmaceutical ingredients for supply to pharmaceutical and biotechnology companies worldwide.
These bile acids have gained popularity with assistance to solubilise non-polar drugs for delivery in aqueous media by injection.
NZP manufactures several refined bile products that are used as selective inhibitory agents in bacteriological media. These include pure sodium salts of bile acids, which are supplied to biotech and media companies worldwide.
NZP’s sister company, Dextra located in Reading, UK, undertakes custom carbohydrate synthesis and offers a catalogue of carbohydrate derivatives for glycobiology and other applications.
NZP manufactures a range of dietary supplement ingredients under GMP conditions.
In consultation with the aquaculture industry, NZP has developed Mixed Bile Acids, which is easily incorporated into feeds.